LINKS
ABOUT
SOCIAL
  • Black LinkedIn Icon
  • Black Twitter Icon

Contact@stemcellerant.com

One Kendall Square

Building 200, Suite 001

Cambridge, MA 02139

© 2019 StemCellerant, LLC

OUR MISSION​

To transition us to a future with personalized regenerative medicine.​
With our unique stem cell differentiation technology, we work to discover new treatments for diseases and also make stem cell therapies safer and more effective.
We work to make regenerative medicine a reality for patients.
 

OUR TECHNOLOGY

​​Revolutionizing medicine by transforming differentiation
Accelerating a new wave of medicines in cell therapy by revolutionizing the differentiation process.  Differentiation is a fundamental biological process that is central to human life and the development of many biomedical applications.
StemCellerant's patented technology is based on the discovery by its founders that allow stem cells to be directly differentiated to usable cell types.  This stem-to-terminal differentiation is called accelerated differentiation.  Previously, to generate usable cells from stem cells, one had to recapitulate many of the normal developmental steps to get to each cell, leading to a very lengthy and often ineffective process.  StemCellerant avoids these problems by bypassing many of the intermediate stages of differentiation to generate a much safer and effective result.
Combined with the Nobel-prize winning discovery of Shinya Yamanaka on dedifferentiation/reprogramming to induced pluripotent stem cells (iPSCs), StemCellerant's technology provides a way to develop next generation stem cell therapies and drugs that will be the future for patients.
REIMAGINE SCIENCE
 

Investors

StemCellerant's long term goal is to help make personalized regenerative medicine a reality.  Towards this end, StemCellerant seeks investors who wish to work together with us towards this vision.  Strategic investors, Institutional Investors, Pharmaceutical companies, Foundations, and Families - we welcome the opportunity to work with you.
 
Past funding sources include the NIH and Harvard's Blavatnik Biomedical Accelerator.
 

GET IN TOUCH

One Kendall Square

Building 200, Suite 001

Cambridge, MA 02139